NCT06691412Not yet recruitingPhase 3
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes
Source: ClinicalTrials.gov · Last updated 15 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In this study, the investigators aimed to evaluate the hepatoprotective effect of OCA against HBV-induced liver injury by comparing patients demographic , laboratory date ( liver function , viremia ) , degree of hepatic steatosis and fibrosis and portal doppler at the beginning and after six months .
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 13 Sept 2024
- Start date
- 15 Nov 2024
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- Assiut University
- Diseases
- Hepatitis B
- NCT number
- NCT06691412
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 100
- From 15 Nov 2024 to the primary completion date, 1 Jan 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients with other viral hepatitis infection .
- portal vein thrombosis.
- Subjects with risk of 2nd hepatic steatosis liver disease (excessive alcohol consumption and medications).
- history of liver disease such as (α-1 antitrypsin deficiency, autoimmune hepatitis, drug-induced liver injury, 1ry biliary cirrhosis, 1ry sclerosing cholangitis).
- Body Mass Index (BMI) \> 35 (to avoid the possibility of Fibroscan failure).
- Patient with end organ disease.
Age
- patients under the age of 18.
Other
- Hepatocellular carcinoma .
Who the study is looking for
- Patients 18 years of age or older who had diagnosed as chronic HBV on treatment with with Controlled Attenuation Parameter (CAP) value more than 238 dB/m .
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.